About This Fund
Atlas Venture Fund XIV is a US$450 million early-stage venture capital fund launched by Atlas Venture, one of the leading life sciences VC firms based in Cambridge, Massachusetts. The fund completed its final close in December 2024 after an oversubscribed fundraising process that general partner Bruce Booth described as 'the smoothest, most efficient, and most oversubscribed fundraise' in the firm's 20-year history of biotech investing — noting the fund could have been raised at several multiples of its target. Fund XIV is led by general partners Kevin Bitterman, Bruce Booth, Michael Gladstone, David Grayzel, and Jason Rhodes, and was backed by a 'marquee group of long-term institutional investors.' The fund maintains an identical size to its predecessor, Fund XIII (US$450 million, closed February 2022), a deliberate choice rooted in the firm's capital discipline philosophy.
Atlas Venture employs a distinctive 'seed-led venture creation model,' where the firm actively co-creates most portfolio companies rather than accepting unsolicited pitches. The partnership builds biotech companies based on scientific discoveries and technologies, typically securing 50-70% initial ownership stakes before dilution through subsequent financing rounds. Fund XIV targets seed and Series A investments in early-stage biotech companies across disease areas, treatment modalities, and business models, with a typical portfolio construction of 20-25 deals per vintage. The fund's capital-constrained approach reflects what Booth has termed the 'VC Math Problem' — larger funds face mathematical constraints in delivering targeted 3x+ net returns given realistic exit value distributions and ownership percentages at later stages.
Atlas Venture manages approximately US$3 billion in total assets across all funds and has operated from a single Cambridge, Massachusetts office since its founding. Fund XIII demonstrated strong early performance with portfolio exits including the acquisition of the Nimbus Tyk2 program, Versanis Bio, Aiolos Bio, and Mariana Oncology, while also launching 16 new biotech businesses since 2022. The broader Atlas portfolio currently includes approximately 50 active clinical trials, reflecting deep scientific engagement across portfolio companies. Fund XIV's close came immediately before Atlas's September 2025 announcement of Opportunity Fund III (US$400 million), the two funds together constituting Atlas's dual-fund model for early-stage creation and later-stage follow-on capital.